Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00425750 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: bortezomib
DRUG: docetaxel
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]